Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)


The Searle Company

Status and phase

Phase 2


HIV Infections


Drug: Butyldeoxynojirimycin
Drug: Zidovudine

Study type


Funder types




Details and patient eligibility


To assess the dose-related antiviral effects of SC-48334 and zidovudine (AZT) administered in combination or individually in HIV-1 positive patients with 200 - 500 CD4+ cells/mm3. To determine the safety of escalating doses of SC-48334 when administered in combination with any of three doses of AZT to symptomatic HIV-1 positive patients with 200 - 500 CD4+ cells/mm3, and to assess the pharmacokinetics of the two drugs, given separately and in combination.




18+ years old


No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

  • Documented HIV infection.
  • CD4 cell count 200 - 500 cells/mm3.
  • Prior therapy with 12 - 48 weeks of AZT.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Clinically significant diarrhea without definable cause (> 3 liquid stools per day for more than 7 days within 6 months prior to study entry).
  • Diarrhea, as above, with known non-HIV-related cause occurring within 1 month prior to study entry.
  • Symptoms meeting CDC criteria for AIDS classification.
  • Fever as a constitutional sign of HIV disease (> 38.5 degrees C persisting for more than 14 consecutive days or for more than 15 days in any given 30-day period prior to study entry).
  • Malignancies, other than basal cell carcinoma and Kaposi's sarcoma (provided patient has fewer than 10 Kaposi's sarcoma lesions, no non-skin lesions, and no requirement for systemic treatment).
  • Significant organ dysfunction.
  • Known hypersensitivity to SC-48334 or AZT or related compounds.

Concurrent Medication:


  • Any investigational drug other than SC-48334.
  • Any anti-HIV drug other than AZT.
  • Cancer chemotherapy.

Patients with the following prior conditions are excluded:

  • History of cataracts or known increased risk of cataract formation.
  • Known hypersensitivity to SC-48334 or AZT or related compounds.
  • History of lactose intolerance.

Prior Medication:


  • Prior SC-48334.
  • Cancer chemotherapy within 6 months prior to study entry.
  • Treatment with any investigational drug or any drug with anti-HIV activity, other than AZT, within 30 days prior to study entry.

Prior Treatment:


Whole-body irradiation within 6 months prior to study entry. Current use of illicit substances, or abuse of alcohol, which would limit compliance with the protocol.

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems